Navigation Links
PharmaVentures Engaged by Avexa to Assist in the Out-licensing of Apricitabine
Date:7/12/2011

OXFORD, England, July 12, 2011 /PRNewswire/ --


 

PharmaVentures Limited, experts in deals and alliances, are pleased to announce that they have been engaged by Avexa Limited to seek an out-licensing partner for apricitabine (ATC), a late-stage, novel treatment for HIV infection.  The engagement will utilise PharmaVentures' global transactional expertise in the healthcare and investment business sectors.

Dr Fintan Walton, CEO, PharmaVentures, commented, "We are delighted to have been chosen by Avexa to assist in achieving its business goal of maximising the return on investment in its development compound apricitabine (ATC).  With 20 years' experience of deals and alliances, PharmaVentures can provide Avexa with immediate access to extensive licensing expertise and a network of key decision makers in relevant companies."

Iain Kirkwood, Chairman of Avexa, said, "The appointment of PharmaVentures to work with and complement our management team is the next logical step in the commercialisation of ATC following our successful regulatory meeting with the FDA earlier this year. PharmaVentures have an excellent reputation and track record in this area."

ATC is a novel nucleoside, a class of compound known to be a vital component of anti-HIV therapy.  ATC offers a new extension to existing therapies in the treatment of drug-resistant HIV, especially for those patients with limited remaining therapeutic options.

PharmaVentures is a leading life sciences transaction advisory firm with strong capabilities in finding and evaluating opportunities and negotiating deals.  The licensing team has an established track record in generating outstanding value for PharmaVentures' clients and has assisted in over 100 transactions in the past 20 years.  

About PharmaVentures Limited

PharmaVentures Limited (http://www.pharmaventures.com) is a leading international corporate advisory firm supporting its clients' growth ambitions in the health care industry. It has considerable experience and expertise in the field of tangible and intangible transactions, providing advice at both a strategic level, as well as acting as advisor and broker at an implementation level. Its transactional experience includes licensing, joint ventures, mergers, acquisitions and divestments. Its clients are worldwide, including Europe, the USA and AsiaPacific. Clients range from start-ups to global pharmaceutical corporations, diversified industrial corporations, investment houses and government bodies. It also produces the highly popular PharmaDeals® (http://www.pharmadeals.net) range of intelligence products including databases, deals analysis and reports as well as the world's first dedicated online pharmaceutical television channel PharmaTelevision® (http://www.pharmatelevision.com).  Now in its 20th year, PharmaVentures is based in Oxford, UK, and employs over 30 people.

About Avexa Limited

Avexa Limited (http://www.avexa.com.au) is a Melbourne-based biotechnology company with a focus on discovery, development and commercialisation of small molecules for the treatment of infectious diseases. Avexa's key projects include apricitabine (ATC) for the treatment of drug-resistant HIV, an HIV integrase program and an antibiotic program for antibiotic-resistant bacterial infections.

For enquiries regarding this licensing opportunity or how we can help your company to achieve its business goals, please contact:

Kevin Bottomley
Head of Transactions
PharmaVentures Ltd.
kevin.bottomley@pharmaventures.com
+44-7931-144097



'/>"/>
SOURCE PharmaVentures
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmaVentures Appoints Paul Phull as Senior Director
2. NeoStem to Launch New Service and Has Engaged Healthcare Personality Dr. Manny Alvarez to Serve as Spokesperson
3. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
4. Medical Messenger Partners With ComputerAssistant.com to Provide Key Elements of Meaningful Use Success
5. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
6. Reportlinker Adds US Cardiac Assist Devices -- Market Trend Till 2016
7. Pharmacy Technicians Assist Pharmacy Teams in Development of Drug Shortage Protocols
8. Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management
9. Lilly USA, LLC Launches TruAssist for Patients
10. Swedish Robotic-Assisted Surgical Program Grows, Continues to Gain Momentum
11. Free Statewide Rx Assistance Program Launching in Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Kitov Pharmaceuticals ... late-stage drug development, today announced the completion of ... batches required for registration of KIT-302 with the ... Kitov,s announcement in December 2015, that ... primary efficacy endpoint. "We are fortunate ...
(Date:5/26/2016)... May 26, 2016 A key ... is the emergence of new treatments. Cardax, a development ... osteoarthritis treatment. The therapy is expected to fulfil large ... UK is conducting studies to develop new treatments for ... the genes involved in osteoarthritis are being investigated, and ...
(Date:5/25/2016)... FDA 510(k) clearance covers Confocal Miniprobes ... and surgical applications Mauna Kea Technologies ... multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced ... the 12 th 510(k) clearance from United ... FDA clearance covers Confocal Miniprobes indicated for use ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... An educational campaign aimed at everyone ... courtesy of awareness-driven celebrities and thought leaders. It also provides insight to the ... leaders such as Bioness. , As patients feel increasingly concerned about the ...
(Date:5/27/2016)... ... May 27, 2016 , ... Beleza Medspa has initiated ... regulations. This is the first time that Coolsculpting is being used for for ... six months to ensure they meet the prescribed body-fat standard, measured by the circumference-based ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at nurses and ... stories, which come courtesy of leaders in the nursing and health care industry. It ... advocates and associations—namely Abilene Christian University. , As the nursing industry is coming ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... trusted name in the pharmaceutical, medical and food industries. Aside from its GMP ... certification (SIC), providing proof of successfully certified products, services and staff. , Validation ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways ... and Sausage Council (NHDSC) suggests that Americans prefer their dogs straight off the grill. ... say grilling is their favorite way to cook a hot dog, far outpacing other ...
Breaking Medicine News(10 mins):